HeYu-B (02256): HeYu Pharmaceuticals will report the latest Phase 2 clinical trial data of the combination therapy of ipilimumab and Atezolizumab for advanced hepatocellular carcinoma at the ESMO GI meeting in 2025.

Wisdom Financial News APP, Heyu-B (02256) announced that its subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medicine) announced today that it will present the latest Phase 2 clinical trial data of Irpagratinib/ABSK-011 in combination with Atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) at the 2025 European Society for Medical Oncology Gastrointestinal Cancer Congress (ESMO GI Congress) to be held in Barcelona, Spain from July 2 to July 5, 2025.